Acadia Healthcare (ACHC) Earnings Date & Reports
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities... Show more
ACHC is expected to report earnings to 37 cents per share on August 04
Acadia Healthcare (ACHC) Q1 2026 Earnings Recap: Revenue and EPS Beat Expectations
Key Takeaways
- Revenue reached $828.8 million, surpassing consensus estimates of $823.5 million and rising 7.6% year-over-year.
- Adjusted earnings per share (EPS) came in at $0.37, beating analyst forecasts of $0.28 by 32%.
- Adjusted EBITDA grew 7% to $144.2 million, exceeding the high end of company guidance.
- Same-facility revenue increased 7.3%, driven by 5.6% higher revenue per patient day and 1.6% more patient days.
- Full-year 2026 guidance raised: Adjusted EBITDA to $580–$615 million, Adjusted EPS to $1.35–$1.60.
- Shares dropped over 20% in after-hours trading despite the beats.
Earnings Context and Why It Matters
Acadia Healthcare, a leading provider of behavioral healthcare services, operates over 250 facilities across the U.S., focusing on inpatient psychiatric care, residential treatment, and outpatient services. This Q1 2026 report is critical amid rising demand for mental health and substance use disorder treatments, post-pandemic capacity expansions, and reimbursement pressures. Investors watch closely for volume trends, payer mix stability, and operational efficiencies, as these signal Acadia's ability to navigate regulatory scrutiny and labor costs in a fragmented industry. Strong results could affirm its growth trajectory, while any weakness in key segments like specialty treatment might raise concerns about profitability.
Acadia reported Q1 2026 revenue of $828.8 million, up 7.6% from $770.5 million in Q1 2025 and above consensus estimates of $823.5 million. The growth was led by acute inpatient facilities (up 14% to $470.7 million), with residential treatment also advancing 6.3%. Same-facility admissions rose 6.5%.
Reported net income fell to $4.1 million ($0.05 diluted EPS) from $8.4 million ($0.09), due to higher interest and legal expenses. However, adjusted net income was $33.3 million ($0.37 diluted EPS), down slightly from $0.40 but beating expectations of $0.28. Adjusted EBITDA hit $144.2 million, a 7% increase that topped prior-year levels and internal guidance.
CEO Debbie Osteen highlighted "strong patient volumes across our Acute and RTC (residential treatment centers) businesses" and operating efficiencies.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.
Market Reaction and Investor Sentiment
Despite topping revenue and EPS estimates, ACHC shares tumbled more than 20% in after-hours and premarket trading on April 30, 2026. The decline overshadowed the results beat, possibly due to the drop in reported net income, a 6.5% decline in specialty treatment revenue, elevated startup losses, and Q2 guidance perceived as conservative amid higher bad debts and denials. Sentiment turned cautious, with focus shifting to near-term pressures.
Forward Outlook and Key Factors to Monitor
Acadia raised its full-year 2026 guidance, boosting Adjusted EBITDA to $580–$615 million (from $575–$610 million) and Adjusted EPS to $1.35–$1.60 (from $1.30–$1.55), reflecting confidence in volume growth and efficiencies. Q2 guidance calls for revenue of $835–$850 million and Adjusted EBITDA of $142–$152 million, incorporating ~$15 million in startup losses and no incremental supplemental payments.
Investors should track bed expansions (82 new beds added in Q1), payer reimbursements, and bad debt trends, as specialty segment recovery and acute demand remain pivotal. Net leverage is projected at 3.9x–4.2x Adjusted EBITDA by year-end, supporting M&A (mergers and acquisitions) potential. Ongoing legal matters and labor costs could pressure margins, while regulatory changes in behavioral health may influence volumes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Advertisement
General Information
an operator of a network of behavioral health centers
Industry HospitalNursingManagement